biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by kuatoliveson Mar 19, 2017 6:59pm

165 Views

Post# 26000136

RE:RE:RE:Abbvie at it again

Yeah, I wouldn't put too much stock in what Abbvie is doing. After all, with a market cap of 104 billion who could buy BTI and all of its patents for pocket lint, they are obviously too dumb to make it work.

Or, and this is a *complete* longshot, BTI's technology is not worth Abbvie's pocket lint.

You guys are hillarious.

Bullboard Posts

Invest wiser with BMO's InvestorLine Platform features